US › Healthcare

Oculis Holding AG Ordinary shares (OCS)

US · Healthcare · Biotechnology

$11.99+0.84%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-29.5M
Profit YoY
+11.2%
EPS
$-0.49
EPS estimate
$-0.41

EPS came in at -0.49 against a street estimate of -0.41 — a miss of 19.5%.

Key statistics

Market cap
$683.0M
Forward P/E
0.0
P/B
2.83
Book value
$3.97
EPS (TTM)
$-2.08
52-week high
$34.48
52-week low
$10.52
50-day MA
$14.45
200-day MA
$22.01
Beta
0.20

Analyst view

Analysts rate Oculis Holding AG Ordinary shares a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $36.08.

Shareholding

Insiders
3.51%
Institutions
39.65%

Largest institutional holders

FundStake
EQT Fund Management S.à r.l.9.77%
Gildi - lifeyrissjodur4.02%
Aberdeen Group PLC2.89%
Pivotal bioVenture Partners Investment Advisor LLC2.78%
Wellington Management Company LLP2.23%
Millennium Management LLC1.51%
Adage Capital Partners Gp LLC1.38%
SR ONE CAPITAL MANAGEMENT, LP1.06%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Oculis Holding AG Ordinary shares — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.